Dr. Kole is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Valley Health Plz
Paramus, NJ 07652Phone+1 201-634-5403Fax+1 201-634-5765
Summary
- I am a board certified Radiation Oncologist at Valley Mount Sinai Comprehensive Cancer Care specializing in the treatment of prostate cancer, diseases of the central nervous system, lung cancer, gastrointestinal cancers, and cancers of the head and neck. My expertise includes the use of Stereotactic Body Radiotherapy (SBRT), Gamma Knife Stereotactic Radiosurgery (SRS), as well as other state-of-the-art radiation techniques for both malignant and benign diseases.
Education & Training
MedStar Health/Georgetown University HospitalResidency, Radiation Oncology, 2011 - 2015
Atlantic Health SystemInternship, Transitional Year, 2010 - 2011
Rutgers New Jersey Medical SchoolClass of 2010
Johns Hopkins UniversityPost-Doctoral Fellowship, Hematology and Medical Oncology, 2004 - 2006
Johns Hopkins UniversityPhD, Chemical and Biomolecular Engineering, 1999 - 2004
Certifications & Licensure
NY State Medical License 2015 - 2026
NJ State Medical License 2015 - 2025
DC State Medical License 2011 - 2012- American Board of Radiology Radiation Oncology
Awards, Honors, & Recognition
- Stanley Bergen Medal of Excellence Rutgers New Jersey Medical School, 2010
- Member Alpha Omega Alpha, 2009
Clinical Trials
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Start of enrollment: 2020 Dec 15
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Start of enrollment: 2021 Nov 03
Publications & Presentations
PubMed
- Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.Michael C Repka, Michael Carrasquilla, Ima Paydar, Binbin Wu, Siyuan Lei
Acta Oncologica. 2023-02-01 - 8 citationsDefinitive hypofractionated radiation therapy for early stage breast cancer: Dosimetric feasibility of stereotactic ablative radiotherapy and proton beam therapy for i...Jonathan W. Lischalk, Hao Chen, Michael C. Repka, Lloyd Campbell, O. Obayomi-Davies
Advances in Radiation Oncology. 2018-07-01 - 18 citationsProstate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?Shaan Kataria, Harsha Koneru, Shan Guleria, Malika Danner, Marilyn Ayoob
Frontiers in Oncology. 2017-07-24
Press Mentions
Valley-Mount Sinai Comprehensive Cancer Care Offering Advanced Imaging to Identify Metastasized Prostate CancerDecember 22nd, 2022- Physician from Valley Health System to Present Live, Interactive Program Addressing Advances in Prostate Cancer TreatmentAugust 25th, 2022
- Improving the Precision of Treatment for Cancer Patients Receiving RadiationApril 7th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
External Links
- websitehttps://thomaskolemd.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
